| NEUROPHARMACOLOGY | 卷:60 |
| Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease | |
| Article | |
| Kovacs, Attila D.1,2  Saje, Angelika4  Wong, Andrew4  Szenasi, Gabor5  Kiricsi, Peter5  Szabo, Eva5  Cooper, Jonathan D.4  Pearce, David A.1,2,3,6  | |
| [1] Univ Rochester, Sch Med & Dent, Ctr Neural Dev & Dis, Rochester, NY 14642 USA | |
| [2] Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA | |
| [3] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA | |
| [4] Kings Coll London, Pediat Storage Disorders Lab,Inst Psychiat, Dept Neurosci,James Black Ctr, Ctr Cellular Basis Behav,MRC Ctr Neurodegenerat, London SE5 9NU, England | |
| [5] EGIS Pharmaceut Plc, Div Preclin Res, Budapest, Hungary | |
| [6] Univ S Dakota, Sanford Sch Med, Dept Pediat, Sioux Falls, SD 57104 USA | |
| 关键词: Juvenile Batten disease; Neuronal ceroid lipofuscinoses; Cln3; AMPA receptor; EGIS-8332; Rotarod; | |
| DOI : 10.1016/j.neuropharm.2010.10.010 | |
| 来源: Elsevier | |
PDF
|
|
【 摘 要 】
Mutations in the CLN3 gene cause juvenile Batten disease, a fatal pediatric neurodegenerative disorder. The Cln3-knockout (Cln3(Delta ex1-6)) mouse model of the disease displays many pathological characteristics of the human disorder including a deficit in motor coordination. We have previously found that attenuation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptor activity in one-month-old Cln3(Delta ex1-6) mice resulted in an immediate improvement of their motor skills. Here we show that at a later stage of the disease, in 6-7-month-old Cln3(Delta ex1-6) mice, acute inhibition of AMPA receptors by a single intraperitoneal injection (1 mg/kg) of the non-competitive AMPA antagonist, EGIS-8332, does not have an immediate effect. Instead, it induces a delayed but prolonged improvement of motor skills. Four days after the injection of the AMPA antagonist, Cln3(Delta ex1-6) mice reached the same motor skill level as their wild type (WT) counterparts, an improvement that persisted for an additional four days. EGIS-8332 was rapidly eliminated from the brain as measured by HPLC-MS/MS. Histological analysis performed 8 days after the drug administration revealed that EGIS-8332 did not have any impact upon glial activation or the survival of vulnerable neuron populations in 7-month-old Cln3(Delta ex1-6) mice. We propose that temporary inhibition of AMPA receptors can induce a prolonged correction of the preexisting abnormal glutamatergic neurotransmission in vivo for juvenile Batten disease. (C) 2010 Elsevier Ltd. All rights reserved.
【 授权许可】
Free
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 10_1016_j_neuropharm_2010_10_010.pdf | 406KB |
PDF